O’Melveny Worldwide
  • Numerous M&A transactions involving Chinese assets, including sale of a leading Chinese Vitamin C producer, auction of a Chinese banking subsidiary by an international conglomerate, spin-offs by multinationals of Chinese divisions and purchase of automotive financial leasing company.
  • Numerous joint ventures between US tech companies and Chinese State-owned enterprises involving satellites, networking hardware, and telephony
  • Restructurings of distressed companies, including China-focused companies with failed variable interest entities
  • Negotiating the form contract used for import of all Hollywood revenue-sharing films into China
  • Extensive work with private equity and venture capital funds on investments, dispositions and restructurings in China, including investment and subsequent restructuring of a leading Chinese coal bed methane company, investment in the largest out-of-home advertising company and investment in a leading Chinese company operating for-profit universities
  • Structuring and negotiating RMB-denominated investment by Chinese domestic funds into offshore companies
  • Representing numerous companies to negotiate equity, mezzanine and debt financings in China
  • Numerous real estate transactions in China, including financings, long-term development partnerships for greenfield projects, and the acquisition and disposal of commercial and residential buildings by international financial institutions in China
  • Numerous transactions involving overseas investment by Chinese companies, including sale of US analog chip company to consortium of Chinese buyers and financing of Chinese iron sands project in Indonesia
  • Formation of small loan companies and other alternative investment structures for investing in distressed assets in China and taking collateral interests
  • Market entry strategy, licensing arrangements and financings for film & television, gaming and Internet companies in China, including formation of joint ventures for distribution, production and exhibition of film and television properties and negotiating licensing arrangements for gaming properties
  • Inversions and financings of numerous Chinese domestic companies in preparation for offshore listing
  • Market entry strategy, financings and joint ventures for new energy companies expanding to China
  • Market entry strategy and investment by life sciences funds into Chinese drug discovery and medical device opportunities, including numerous financings of drug discovery companies that have subsequently gone public
  • Purchase of non-performing loan portfolios from Chinese banks

Languages

  • Mandarin Chinese

Admissions

Bar Admissions

  • New York

Education

  • Columbia University, J.D., 1995: Harlan Fiske Stone Scholar
  • Williams College, B.A., 1990: cum laude

Honors & Awards

  • Recognized by Chambers Global in the Corporate/M&A category for the China region (2020-2026)
  • Recognized by Chambers Asia-Pacific for Corporate/M&A: China-based (International Firms) (2008-2024) & Private Equity: Buyouts & Venture Capital Investment (International Firms) (2008-2023)
  • Asia-Pacific Legal 500 (2021-2024): Hall of Fame lawyer for the categories of M&A and Private Equity in China
  • Recognized by IFLR1000 as a "Leading Lawyer" (2022) and "Highly Regarded" (2018-2022) in Mergers & Acquisitions and Private Equity
  • Asia-Pacific Legal 500 (2008-2020): Leading Individual lawyer for the categories of M&A and Private Equity in China